Drug Profile
Rheumatoid arthritis therapeutic tetrapeptide
Alternative Names: PTL 0401Latest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator Unknown
- Developer Acambis; BTG
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 13 Jul 1998 Discontinued-II for Rheumatoid arthritis in United Kingdom (Intra-articular)
- 23 Oct 1997 Phase-II clinical trials for Rheumatoid arthritis in United Kingdom (Intra-articular)